# A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

> **NCT07059403** · PHASE1 · RECRUITING · sponsor: **Chimivac INC** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Hepatitis B Infection

## Interventions

- **BIOLOGICAL:** SN2001
- **BIOLOGICAL:** SN2001
- **BIOLOGICAL:** SN2001

## Key facts

- **NCT ID:** NCT07059403
- **Lead sponsor:** Chimivac INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059403, "A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07059403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*